Guotai Junan and Haitong Securities to Launch $10 Billion in Industry Funds in Shanghai
China’s prominent financial institutions, Guotai Junan Securities and Haitong Securities, have revealed plans to establish...
Fineline Cube
Eisai Co., Ltd Secures Asia-Pacific Rights for Fungal Drug with Sato Pharma Deal
Eisai Co., Ltd, (TYO: 4523) a leading Japanese pharmaceutical company, has entered into a strategic...
Sionna Therapeutics Secures Cystic Fibrosis Portfolio in Licensing Deal with AbbVie
US-based biotechnology company Sionna Therapeutics has announced a significant licensing agreement with fellow US firm...
Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo (efgartigimod alfa SC) in gMG
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE (NASDAQ: ARGX)...
Mabwell Bioscience Lands Orphan Drug Status for B7-H3 Targeting ADC in Small Cell Lung Cancer
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has been granted Orphan Drug Designation (ODD) by...
Shanghai Pharmaceuticals Secures NMPA Nod for Roche’s Valcyte Generic
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that it has received marketing approval...
Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs
Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research...
Jiangsu Simcere Pharmaceutical’s Quviviq Approval Application Accepted for Review by China’s NMPA
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), in partnership with Swiss pharmaceutical firm Idorsia Pharmaceuticals...
Jiangsu Hengrui Pharmaceuticals Faces FDA Setback with Warning Letter for Quality Control Issues
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a prominent player in China’s pharmaceutical industry, has received a...
Ocumension Therapeutics and Shandong Boan Biotechnology File for Market Approval of Biosimilar Aflibercept in China
Ocumension Therapeutics (HKG: 1477) and Shandong Boan Biotechnology Co., Ltd (HKG: 6955) have jointly announced...
Sino Biopharmaceutical’s Anlotinib Achieves Milestones in Phase III Trial for Soft-Tissue Sarcoma
Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced positive...
Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...
I-Mab Shakes Up Leadership with New Chairman and Interim CEO Appointments
I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company, has announced significant changes to its leadership structure....
United Imaging Expands Latin America Footprint with Pediatric uMI 550 PET/CT Launch in Mexico
United Imaging, a leading Chinese medical device manufacturer, has announced the launch of its uMI...
MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has announced a...
Eli Lilly’s Lupus Treatment LY3361237 Misses Mark in Phase II Trial
Eli Lilly & Co. (NYSE: LLY) has encountered a setback in its drug development pipeline...
BeiGene Receives NMPA Greenlight for BG-C9074 Clinical Trial in Advanced Solid Tumors
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National Medical Products Administration...
Celling Biotechnology’s CEL001 Earns Tacit Approval for Clinical Trials in China
Celling Biotechnology Co., Ltd, a Guangzhou-based biopharmaceutical company, has announced that its pipeline candidate CEL001...
Sino Biopharmaceutical’s Rovadicitinib Gets CDE Nod for Review in Myelofibrosis
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the Center for Drug Evaluation (CDE) in...
Sichuan Huiyu’s HY07121 Antifungal Protein Earns NMPA Review for Clinical Trials
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese biopharmaceutical company, has announced that the...